GlassScriptPhysician profile
Melissa B Wallace
NPI 1497027247
$2,991.94
in general payments reported to CMS, 2019-2025
31 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $682 · 2022: $697 · 2023: $733 · 2024: $614 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.92 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $291.79 | 2021-2025 | |
| Sage Therapeutics, LLC | $277.41 | 2021-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $221.93 | 2021-2024 | Twirla |
| Exeltis, USA INC. | $212.04 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $193.65 | 2021-2022 | |
| Evofem Biosciences, INC. | $170.80 | 2022-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $127.54 | 2021-2022 | |
| Myriad Women'S Health, INC. | $102.49 | 2023 | Myrisk |
| Astellas Pharma US INC | $101.94 | 2024-2025 | Veozah |
| Organon LLC | $88.61 | 2023-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $51.85 | 2023-2024 | Myfembree |
| Pfizer INC. | $51.61 | 2023-2025 | |
| Myovant Sciences INC. | $49.83 | 2021-2022 | |
| Hologic Sales and Service, LLC | $47.22 | 2023 | Thinprep 2000 Processor, Third Wave, Aptima |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.65 | 2022 | |
| Exact Sciences Corporation | $42.89 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $42.37 | 2022-2023 | Contrave |
| Bayer Healthcare Pharmaceuticals INC. | $39.22 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $38.71 | 2023-2024 | Caldolor |
| Mylan Pharmaceuticals INC. | $34.62 | 2021 | |
| Virtus Pharmaceuticals LLC | $30.14 | 2021 | |
| Novo Nordisk INC | $29.83 | 2023 | Wegovy |
| Shield Therapeutics INC | $27.62 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $23.70 | 2022 | |
| Lsi Solutions INC | $18.22 | 2024 | Fornisee |
| Dexcom, INC. | $15.73 | 2023 | Dexcom G6 Transmitter |
| Millicent US INC | $15.65 | 2025 | Femlyv |
| Ibsa Pharma INC. | $14.50 | 2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $14.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.98 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.